Breaking News

Quotient Clinical Completes Innovative First-in-human Program

Publishes results from Enabled-First-in-Human program conducted for the Janssen WAVE Early Development unit.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Quotient Clinical has announced the results from an Enabled-First-in-Human (Enabled-FIH) program conducted for the Janssen WAVE Early Development unit. The integrated pharmaceutical development and first-in-human clinical program was designed to develop an optimal oral formulation, in parallel with the assessment of single and multiple dose safety, pharmacokinetics and pharmacodynamics of a highly selective small molecule c-Met tyrosine kinase inhibitor. The clinical phase, which was conducte...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters